Valuation: Arctic Bioscience

Market Cap 69.28M 7.48M 6.71M 6.2M 5.62M 10.5M 712M 10.62M 74.17M 29.54M 373M 28.06M 27.47M 1.18B P/E 2026 *
-2.89x
P/E 2027 * -
Enterprise Value 135M 14.6M 13.1M 12.11M 10.97M 20.5M 1.39B 20.74M 145M 57.69M 728M 54.8M 53.64M 2.31B EV / Sales 2026 *
2.33x
EV / Sales 2027 * -
Free-Float
45.02%
Yield 2026 *
-
Yield 2027 * -
1 day-6.61%
1 week+14.29%
Current month-7.69%
1 month-12.09%
3 months-14.29%
6 months-29.41%
Current year-26.83%
1 week 2.05
Extreme 2.05
2.6
1 month 2.05
Extreme 2.05
2.8
Current year 2.05
Extreme 2.05
3.67
1 year 2.05
Extreme 2.05
4.2
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 01/01/2011
Chief Executive Officer 54 01/03/2022
Director of Finance/CFO 47 01/04/2022
Director TitleAgeSince
Chairman 68 01/12/2015
Director/Board Member 55 01/01/2015
Director/Board Member 46 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/23 A Buy

Director

943,833 3.8641%
4/24/23 A Buy

Director

943,833 3.8641%
2/23/23 A Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-6.61%+14.29%-27.71%-73.91% 7.43M
+0.97%+1.74%+57.65%+128.55% 1,143B
+0.91%+5.21%+45.09%+84.46% 647B
+0.03%+0.61%+25.93%+101.95% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-0.94%-6.39%+61.21%+36.64% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.52%+2.50%+53.82%+70.71% 242B
-0.14%+3.36%+34.65%+104.10% 197B
Average -0.55%+1.47%+33.70%+59.54% 402.75B
Weighted average by Cap. +0.34%+0.71%+44.57%+87.09%

Financials

2026 *2027 *
Net sales 58M 6.26M 5.62M 5.19M 4.7M 8.79M 596M 8.89M 62.1M 24.73M 312M 23.5M 23M 991M -
Net income -24M -2.59M -2.32M -2.15M -1.95M -3.64M -247M -3.68M -25.7M -10.23M -129M -9.72M -9.52M -410M -
Net Debt 66M 7.12M 6.39M 5.91M 5.35M 10M 679M 10.12M 70.66M 28.14M 355M 26.74M 26.17M 1.13B -
Projected Income Statement - Annual - Arctic Bioscience
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
28/10/26 NOK 2.400 -6.61% 7,278
27/10/26 NOK 2.570 -1.15% 100
26/10/26 NOK 2.600 +10.17% 1,000
23/10/26 NOK 2.360 +3.06% 1,010
22/10/26 NOK 2.290 +9.05% 1,847
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - Arctic Bioscience

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Arctic Bioscience